ArticleJournal of traditional and complementary medicine2026
Article in Journal of traditional and complementary medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and aim: Breast cancer bone metastasis (BCBM) has a high incidence in clinical settings, resulting in decreased life expectancy and quality of life. Previous research has shown that Experimental procedure: The inhibitory role of SSP on BCBM was determined by cytotoxicity, colony formation assays, invasion, and migration in triple-negative breast cancer (TNBC) cells, and osteoclast differentiation in RANKL-induced RAW 264.7 cell lines. The progression of bone metastasis and overall survival of mice were determined using the BCBM mouse model. Results and conclusion: SSP treatment significantly reduced TNBC proliferation, migration, invasion, and colony formation and inhibited osteoclast differentiation. Additionally, SSP significantly decreased the expression of bone-related marker genes, such as tartrate-resistant acid phosphatase, cathepsin K, and osteoclast-associated receptors. SSP administration effectively reduced the progression of bone metastasis and prolonged the survival time of mice compared to that of the control. The expression level of Dickkopf-1 was also downregulated after SSP treatment, which may account for SSP's anti-bone metastasis mechanism. Overall, SSP exerts therapeutic effects by mitigating colony formation, invasion, migration, metastasis, osteoclast differentiation, and osteolytic destruction. This may provide new drugs for the prevention and treatment of BCBM.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.